Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 582

1.

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.

Jain T, Sauter CS, Shah GL, Maloy MA, Chan J, Scordo M, Avecilla ST, Batlevi Y, Dahi PB, Batlevi CW, Lia Palomba M, Giralt SA, Perales MA.

Leukemia. 2019 May 21. doi: 10.1038/s41375-019-0476-y. [Epub ahead of print] No abstract available.

PMID:
31114023
2.

Racial disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis.

Barker JN, Boughan K, Dahi PB, Devlin SM, Maloy MA, Naputo K, Mazis CM, Davis E, Nhaissi M, Wells D, Cooper C, Ponce DM, Kernan N, Scaradavou A, Giralt SA, Papadopoulos EB, Politikos I.

Blood Adv. 2019 Apr 9;3(7):939-944. doi: 10.1182/bloodadvances.2018028662.

3.

Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma.

Dahi PB, Moskowitz CH, Giralt SA, Lazarus HM.

Expert Rev Hematol. 2019 Mar 18:1-12. doi: 10.1080/17474086.2019.1596793. [Epub ahead of print]

PMID:
30884247
4.

Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.

Dahi PB, Moskowitz CH, Giralt SA, Lazarus HM.

Expert Rev Hematol. 2019 Apr;12(4):255-264. doi: 10.1080/17474086.2019.1593135. Epub 2019 Mar 21.

PMID:
30874456
5.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC.

Leukemia. 2019 Apr;33(4):1058-1059. doi: 10.1038/s41375-019-0410-3.

PMID:
30842604
6.

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C, Shah GL, Maloy MA, Papadopoulos EB, Jakubowski AA, Avecilla ST, O'Reilly RJ, Castro-Malaspina H, Tamari R, Shaffer BC, Boelens JJ, Perales MA, Giralt SA.

Biol Blood Marrow Transplant. 2019 Mar 1. pii: S1083-8791(19)30146-6. doi: 10.1016/j.bbmt.2019.02.021. [Epub ahead of print]

PMID:
30831208
7.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, Horowitz MM, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J.

Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.

PMID:
30824040
8.

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG).

Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, Dimopoulos MA, Rajkumar SV, Durie BBG, Terpos E.

Blood Cancer J. 2019 Feb 26;9(3):27. doi: 10.1038/s41408-019-0187-7.

9.

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A.

J Clin Oncol. 2019 Mar 1;37(7):589-597. doi: 10.1200/JCO.18.00685. Epub 2019 Jan 17.

PMID:
30653422
10.

Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.

Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Maloy M, Castro-Malaspina H, Giralt SA, Weinberg RS, Mascarenhas JO, Mesa R, Rondelli D, Dueck AC, Levine RL, Gupta V, Hoffman R, Rampal RK.

Biol Blood Marrow Transplant. 2019 Jan 6. pii: S1083-8791(19)30005-9. doi: 10.1016/j.bbmt.2019.01.002. [Epub ahead of print]

PMID:
30625392
11.

Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Hsu M, Jakubowski AA, Shah GL, Cho C, Maloy MA, Avecilla ST, Papadopoulos EB, Gyurkocza B, Castro-Malaspina H, Tamari R, O'Reilly RJ, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2019 Jan 6. pii: S1083-8791(19)30011-4. doi: 10.1016/j.bbmt.2018.12.842. [Epub ahead of print]

PMID:
30625387
12.

Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.

Lin RJ, Hilden PD, Elko TA, Dahi PB, Shahrokni A, Jakubowski AA, Perales MA, Sauter CS, Castro-Malaspina HR, Barker JN, Shaffer BC, Tamari R, Papadopoulos EB, Maloy MA, Korc-Grodzicki B, Giralt SA.

Blood Adv. 2019 Jan 8;3(1):12-20. doi: 10.1182/bloodadvances.2018028241.

13.

Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.

Xiao W, Goldberg AD, Famulare C, Devlin S, Nguyen N, Sim S, Kabel CC, Patel MA, McGovern E, Patel A, Schulman J, Dunbar A, Epstein-Peterson ZD, Menghrajani K, Getta BM, Cai SF, Geyer MB, Glass J, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt S, Klimek V, Tallman MS, Roshal M.

Haematologica. 2018 Dec 6. pii: haematol.2018.203018. doi: 10.3324/haematol.2018.203018. [Epub ahead of print]

14.

Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.

Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, Jakubowski AA, Castro-Malaspina HR, Robinson KS, Papadopoulos EB, Perales MA, Sauter CS.

Br J Haematol. 2019 Mar;184(6):1006-1010. doi: 10.1111/bjh.15721. Epub 2018 Dec 11.

PMID:
30537212
15.

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Xiao W, Bharadwaj M, Levine M, Farnhoud N, Pastore F, Getta BM, Hultquist A, Famulare C, Medina JS, Patel MA, Gao Q, Lewis N, Pichardo J, Baik J, Shaffer B, Giralt S, Rampal R, Devlin S, Cimera R, Zhang Y, E Arcila M, Papaemmanuil E, Levine RL, Roshal M.

Blood Adv. 2018 Dec 11;2(23):3526-3539. doi: 10.1182/bloodadvances.2018023531. Erratum in: Blood Adv. 2019 Apr 9;3(7):956.

16.

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Giralt S, Seifter E.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):103-109. doi: 10.1182/asheducation-2018.1.103. Review.

PMID:
30504298
17.

Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes.

Huang YT, Su Y, Kim SJ, Nichols P, Burack D, Maloy M, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA.

Biol Blood Marrow Transplant. 2019 Apr;25(4):791-799. doi: 10.1016/j.bbmt.2018.11.012. Epub 2018 Nov 24.

PMID:
30476551
18.

The timing and widespread effects of the largest Holocene volcanic eruption in Antarctica.

Antoniades D, Giralt S, Geyer A, Álvarez-Valero AM, Pla-Rabes S, Granados I, Liu EJ, Toro M, Smellie JL, Oliva M.

Sci Rep. 2018 Nov 22;8(1):17279. doi: 10.1038/s41598-018-35460-x.

19.

Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.

Dahi PB, Lazarus HM, Sauter CS, Giralt SA.

Bone Marrow Transplant. 2018 Nov 2. doi: 10.1038/s41409-018-0378-z. [Epub ahead of print] Review.

PMID:
30390059
20.

Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.

Malard F, Labopin M, Cho C, Blaise D, Papadopoulos EB, Passweg J, O'Reilly R, Forcade E, Maloy M, Volin L, Castro-Malaspina H, Hicheri Y, Jakubowski AA, Orvain C, Giralt S, Mohty M, Nagler A, Perales MA.

J Hematol Oncol. 2018 Oct 20;11(1):127. doi: 10.1186/s13045-018-0668-3.

Supplemental Content

Loading ...
Support Center